Benzeneethanamine, alpha-ethyl-, (alphaR)- | 30543-89-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzeneethanamine, alpha-ethyl-, (alphaR)-
• 英文别名: (2R)-1-phenylbutan-2-amine
• CAS: 30543-89-6
• 化学式: C₁₀H₁₅N
• 分子量: 149.236
• InChiKey: IOLQWLOHKZENDW-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-chloro-6-deoxy-5'-ethylamino-2',3'-isopropylidene-5'-oxo-5'-deoxyinosine 、 Benzeneethanamine, alpha-ethyl-, (alphaR)- 在 三乙胺 作用下， 以 乙醇 为溶剂， 反应 48.0h， 生成
  参考文献：
  名称：

  N6-Substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors

  摘要：

  The coronary vasoactivity of N-ethyl-1'-deoxy-1'-(6-amino-9H-purin-9-yl)-beta-D-ribofuranuronamide (NECA, 1) is over 2 orders of magnitude greater than that of adenosine, and the vasoactivity of certain N6-substituted adenosines is as much as 1 order of magnitude greater. Such results suggest that a combination of appropriate modifications at N6 and C-5' might additively augment the agonist potency of adenosine. At low temperatures 1-deoxy-1-(6-chloro-9H-purin-9-yl)-2',3'-O-isopropylidene- beta-D-ribofuranosyl chloride (5), obtained in three steps from inosine, reacts with amines to yield uronamides. The subsequent reaction of such uronamides with amines at elevated temperatures displaces the purine 6-chloro group to yield, after deblocking, N-alkyl(or aryl)-N6-alk(ar)yl-adenosine-5'-uronamides. At the coronary artery A2 receptor the potency of N6-modified analogues of 1 is similar to that of the N6-substituted adenosine, rather than equal to or greater than 1. As agonists in the A2 receptor-mediated stimulation of adenylate cyclase in plasma membranes of PC12 pheochromocytoma cells or human platelets, N6-substituted analogues of 1 are intermediate between the high potency of 1 and the lower potency of the N6-substituted adenosines. At the A1 receptor of rat brain the potency of an N6-substituted analogue of 1 is often greater than that of the corresponding N6-substituted adenosine. At all four receptors, replacing the ethyl group of N-ethyl-N6-3-pentyladenosine-5'-uronamide by larger alkyl groups reduces potency; amides of secondary amines are inactive or have only marginal activity. Analogues of 1 containing a chiral center in the N6 substituent retain the stereoselectivity characteristic of each of the four receptors. Thus, at either A1 or A2 adenosine receptors, adenosine analogues interact with both the N6 and the C-5' receptor regions. However, the effects of N6 and C-5' modifications on potency are less than additive, evidence that the interaction of a substituent with its receptor region influences the interaction of other substituents with their respective receptor regions.

  DOI：

  10.1021/jm00159a020
• 作为产物：
  描述：

  1-苯基-2-丁酮 在 Cb-FDH formate dehydrogenase (variant) from Candida boidinii 、 Rs-PhAmDH amine dehydrogenase variant from the phenylalanine dehydrogenase from Rhodoccoccus species 、 β-烟酰胺腺嘌呤二核苷酸 、 甲酸铵 作用下， 以 水 为溶剂， 反应 48.0h， 以99%的产率得到
  参考文献：
  名称：

  胺脱氢酶：羰基化合物还原胺化的高效生物催化剂

  摘要：

  胺是生产大量化合物的主要目标，这些化合物在制药、农业化学和大宗化学工业中有应用。然而，不对称合成...

  DOI：

  10.1039/c6gc01987k

文献信息

• In vitro biocatalytic pathway design: orthogonal network for the quantitative and stereospecific amination of alcohols
  作者：Tanja Knaus、Luca Cariati、Marcelo F. Masman、Francesco G. Mutti

  DOI：10.1039/c7ob01927k

  日期：——

  cycle generates the related amine products with >99% enantiomeric excess (R) and up to >99% conversion. The elevated conversions stem from the favorable thermodynamic equilibrium (K′eq = 1.88 × 1042 and 1.48 × 1041 for the amination of primary and secondary alcohols, respectively). This biocatalytic network possesses elevated atom efficiency, since the reaction buffer (ammonium formate) is both the aminating

  醇直接有效转化为胺是化学中的关键性转变。在这里，我们介绍了一个人工的氧化还原生物催化网络，该网络在两个并发且正交的循环中使用了五种酶（酒精脱氢酶，NADP氧化酶，过氧化氢酶，胺脱氢酶和甲酸脱氢酶）。NADP依赖的氧化循环将多种芳香族和脂族醇底物转化为羰基化合物中间体，而NAD依赖的还原胺化循环产生相关的胺产物，其对映体过量（R）> 99％转换。升高的转化从有利热力学平衡杆（ķ '当量= 1.88×10 42 1.48×1041分别用于伯醇和仲醇的胺化）。该生物催化网络具有提高的原子效率，因为反应缓冲液（甲酸铵）既是胺化剂又是还原当量的来源。另外，仅需要双氧，而水和碳酸盐是副产物。对于氧化步骤，我们使用了乙醇嗜热厌氧菌NADP依赖性醇脱氢酶的三个变体，并借助计算机计算模型阐明了这些变体的立体选择性性质的起源。
• [EN] ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS<br/>[FR] TRANSAMINATION ENZYMATIQUE D'ANALOGUES DE CYCLOPAMINE
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2011017551A1

  公开（公告）日：2011-02-10

  Provided are processes for the synthesis of amino analogues from ketone starting materials

  提供从酮起始材料合成氨基类似物的过程。
• 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
  申请人：Taveras G. Arthur

  公开号：US20070021494A1

  公开（公告）日：2007-01-25

  There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

  公开了以下化合物的公式或其药学上可接受的盐或溶剂，它们可用于治疗趋化因子介导的疾病，如急性和慢性炎症性疾病和癌症。
• 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS
  申请人：Taveras Arthur G.

  公开号：US20090306079A1

  公开（公告）日：2009-12-10

  There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

  公开了以下式子的化合物，或其药学上可接受的盐或溶剂，其对于化学因子介导的疾病如急慢性炎症性疾病和癌症的治疗是有用的。
• BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS
  申请人：Harris Joel M.

  公开号：US20110065671A1

  公开（公告）日：2011-03-17

  The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bi-cyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.

  本发明涉及式(I)的二环杂环衍生物，包括一种二环杂环衍生物的组合物，并且还涉及使用这些二环杂环衍生物来治疗或预防患者的肥胖症、糖尿病、代谢障碍、心血管疾病或与GPR1 19活性相关的疾病的方法。